Brief: Chemomab Announces FDA Clearance Of IND Application For CM-101

Chemomab Therapeutics

02/12/2021 12:58

Dec 2 (Reuters) - Chemomab Therapeutics Ltd  CMMB.O :
    * CHEMOMAB ANNOUNCES FDA CLEARANCE OF ITS IND APPLICATION
FOR
CM-101, A FIRST-IN-CLASS CCL24 NEUTRALIZING ANTIBODY FOR THE
TREATMENT OF PRIMARY SCLEROSING CHOLANGITIS
    * CHEMOMAB - PHASE 2 SPRING TRIAL ASSESSING CM-101 AS
POTENTIAL
TREATMENT FOR PSC IS UNDERWAY IN EUROPE, ISRAEL
    * CHEMOMAB THERAPEUTICS - PHASE 2 SPRING TRIAL ASSESSING
CM-101 AS
A POTENTIAL TREATMENT FOR PSC IS NOW BEING EXPANDED TO INCLUDE
U.S. SITES
    * CHEMOMAB THERAPEUTICS - INITIAL CLINICAL READOUT FROM
SPRING
TRIAL IS EXPECTED IN 2022

Source text for Eikon:  ID:nPn24Mj2Ka 
Further company coverage:  CMMB.O 

 ((Reuters.Briefs@thomsonreuters.com;))